MORPHINE Drug Interactions
Also known as: Opium Tincture Deodorized
MORPHINE (brand name: Opium Tincture Deodorized) is a Opioid Analgesics. INDICATIONS AND USAGE Opium tincture is useful for the treatment of diarrhea.MORPHINE has 17 documented drug interactions in our database, including 3 contraindicated, 14 major, 0 moderate, and 0 minor interactions.
3
Contraindicated
14
Major
0
Moderate
0
Minor
The combination significantly increases the risk of severe respiratory depression, profound sedation, coma, and death. Patients may experience decreased level of consciousness, hypoventilation, hypoxia, and hypotension. Psychomotor impairment and an increased risk of falls are also common.
Mechanism
Morphine, an opioid agonist, primarily acts on mu-opioid receptors in the central nervous system (CNS) to produce analgesia and respiratory depression. Lorazepam, a benzodiazepine, enhances the effect of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) at GABA-A receptors. The co-administration of these two CNS depressants leads to additive or synergistic depression of the CNS, particularly affecting respiratory drive.
Clinical Management
Concomitant use of opioids and benzodiazepines should generally be avoided due to the high risk of severe adverse outcomes, as highlighted by an FDA Black Box Warning. If co-prescription is absolutely necessary and no alternatives are available, use the lowest effective doses and shortest possible duration, monitor patients closely for respiratory depression and sedation, and counsel them on the risks. Naloxone should be readily available for opioid overdose reversal.
The concurrent use of morphine and temazepam significantly increases the risk of severe adverse effects including profound sedation, respiratory depression, coma, and death. Patients may experience decreased level of consciousness, hypoventilation, hypotension, and psychomotor impairment. This combination can lead to life-threatening respiratory insufficiency.
Mechanism
Morphine, an opioid agonist, binds to mu-opioid receptors in the central nervous system (CNS), leading to CNS depression, analgesia, and respiratory depression. Temazepam, a benzodiazepine, enhances the effect of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) at GABA-A receptors, also resulting in CNS depression, sedation, and anxiolysis. The synergistic CNS depressant effects of both drugs lead to profound respiratory depression.
Clinical Management
Concomitant use of opioids and benzodiazepines should generally be avoided due to the high risk of severe adverse outcomes, including respiratory depression and death. If no alternative treatment options are adequate, the lowest effective doses should be used for the shortest possible duration, with close monitoring for respiratory depression and sedation. Patients should be educated on the risks and signs of overdose, and naloxone should be considered for at-risk patients.
Concomitant use significantly increases the risk of severe respiratory depression, profound sedation, coma, and death. Patients may experience decreased level of consciousness, hypoventilation, bradycardia, and hypotension. This interaction poses a life-threatening risk.
Mechanism
Morphine, an opioid agonist, and chlordiazepoxide, a benzodiazepine, both produce central nervous system (CNS) depression by different mechanisms. Opioids primarily act on mu-opioid receptors, while benzodiazepines enhance the effect of the inhibitory neurotransmitter GABA at the GABA-A receptor. The synergistic CNS depressant effects lead to profound respiratory depression, sedation, and hypotension.
Clinical Management
The co-administration of morphine and chlordiazepoxide is contraindicated due to the high risk of severe adverse outcomes. If concurrent use is unavoidable, which should be rare, patients must be closely monitored for respiratory depression and sedation, and doses should be significantly reduced. Naloxone and flumazenil should be readily available for emergency reversal.
Patients may experience increased sedation, dizziness, confusion, and psychomotor impairment. The most serious clinical effect is an elevated risk of respiratory depression, which can be life-threatening. Impaired motor coordination and cognitive function can also increase the risk of falls and accidents.
Mechanism
Both morphine, an opioid analgesic, and cyclobenzaprine, a centrally acting skeletal muscle relaxant, exert depressant effects on the central nervous system (CNS). This interaction is primarily pharmacodynamic, leading to an additive effect on GABAergic and other inhibitory neurotransmitter systems, resulting in enhanced CNS depression.
Clinical Management
Concomitant use should be avoided if possible. If co-administration is necessary, start with lower doses of one or both medications and monitor patients closely for signs of CNS depression, particularly respiratory depression and excessive sedation. Educate patients about the risks and advise against operating heavy machinery or driving.
Patients may experience profound sedation, dizziness, confusion, and impaired cognitive function. The most serious clinical effect is an increased risk of respiratory depression, which can be life-threatening. Additionally, motor incoordination and falls are more likely, especially in elderly patients.
Mechanism
Both morphine, an opioid analgesic, and methocarbamol, a centrally acting muscle relaxant, exert their primary effects by depressing the central nervous system (CNS). When co-administered, their individual CNS depressant actions are additive, leading to an enhanced overall depressant effect. This includes synergistic depression of respiratory drive, sedation, and psychomotor function.
Clinical Management
Concomitant use should generally be avoided. If co-administration is unavoidable, initiate both medications at the lowest effective doses and titrate cautiously while closely monitoring for signs of CNS and respiratory depression. Educate patients about the risks and advise against driving or operating heavy machinery.
Patients may experience severe sedation, profound respiratory depression, coma, and even death. Other clinical effects include dizziness, confusion, impaired psychomotor function, and hypotension. The risk is heightened due to carisoprodol's metabolism to meprobamate, which significantly contributes to CNS depression.
Mechanism
Morphine is an opioid agonist that causes central nervous system (CNS) depression by binding to mu-opioid receptors. Carisoprodol is a centrally acting skeletal muscle relaxant that also produces CNS depression, partly through its active metabolite meprobamate, which has anxiolytic and sedative properties. The co-administration of these agents results in an additive depressant effect on the CNS.
Clinical Management
Avoid concomitant use of morphine and carisoprodol whenever possible. If co-administration is unavoidable, initiate with the lowest effective doses of both drugs and titrate carefully, monitoring closely for signs of respiratory depression and sedation. Educate patients about the risks and advise against operating heavy machinery or driving. Consider alternative non-opioid analgesics or non-benzodiazepine muscle relaxants.
Patients may experience profound sedation, respiratory depression, hypotension, and impaired psychomotor function. This can manifest as excessive drowsiness, confusion, dizziness, and difficulty breathing, potentially leading to falls, aspiration, and life-threatening respiratory arrest. The combination significantly increases the risk of overdose symptoms.
Mechanism
Morphine, an opioid analgesic, exerts its effects primarily through mu-opioid receptor agonism, leading to central nervous system (CNS) depression. Baclofen, a gamma-aminobutyric acid (GABA)-B receptor agonist, also causes CNS depression by hyperpolarizing neurons and reducing neurotransmitter release. The co-administration of these agents results in an additive depressant effect on the CNS.
Clinical Management
Concomitant use should be avoided if possible. If co-administration is necessary, initiate both medications at the lowest effective doses and titrate cautiously, closely monitoring for signs of CNS and respiratory depression. Educate patients and caregivers on the symptoms of excessive sedation and respiratory depression, advising them to seek immediate medical attention if these occur. Consider prescribing naloxone for at-risk patients.
Patients may experience profound sedation, respiratory depression, hypotension, dizziness, confusion, and impaired psychomotor function. This can lead to an increased risk of falls, accidental injury, and life-threatening respiratory compromise. The risk is heightened in elderly patients or those with pre-existing respiratory conditions.
Mechanism
Both morphine, an opioid analgesic, and tizanidine, an alpha-2 adrenergic agonist muscle relaxant, are central nervous system (CNS) depressants. Their co-administration leads to an additive depressant effect on the CNS, enhancing sedation and respiratory depression. Tizanidine also has hypotensive effects that can be additive with opioids.
Clinical Management
Avoid concurrent use of morphine and tizanidine if possible. If co-administration is unavoidable, start with lower doses of both medications and titrate carefully, monitoring closely for signs of CNS and respiratory depression. Educate patients on the risks and advise against driving or operating heavy machinery.
Patients may experience profound sedation, dizziness, confusion, and psychomotor impairment. The most serious clinical effect is an increased risk of respiratory depression, which can be life-threatening. Hypotension and syncope may also occur.
Mechanism
Morphine, an opioid agonist, primarily acts on mu-opioid receptors in the central nervous system (CNS) to produce analgesia and CNS depression. Metaxalone is a centrally acting muscle relaxant, whose exact mechanism is not fully understood but is thought to involve general CNS depression. The co-administration of these agents results in additive depressant effects on the CNS.
Clinical Management
Concomitant use of morphine and metaxalone should be avoided or used with extreme caution if no alternative treatments are adequate. If co-administration is necessary, initiate with the lowest effective doses of both drugs and titrate slowly while closely monitoring for signs of CNS and respiratory depression. Educate patients and caregivers about the risks and symptoms of CNS depression and respiratory depression.
Patients may experience profound sedation, dizziness, and impaired psychomotor function, increasing the risk of falls and accidents. There is a significant risk of respiratory depression, which can be life-threatening, particularly in opioid-naive individuals or those with underlying respiratory compromise. Cognitive impairment and decreased level of consciousness are also common.
Mechanism
Morphine, an opioid analgesic, exerts its effects primarily through mu-opioid receptor agonism in the central nervous system (CNS), leading to dose-dependent CNS depression. Chlorzoxazone, a centrally acting muscle relaxant, also causes generalized CNS depression, though its precise mechanism is not fully elucidated but involves inhibition of polysynaptic reflexes. The concomitant use of these agents results in an additive depressant effect on the CNS.
Clinical Management
Concomitant use should be avoided if possible. If unavoidable, initiate both medications at the lowest effective doses and titrate cautiously, closely monitoring for signs of CNS and respiratory depression. Educate patients on the risks and advise against operating heavy machinery or driving. Consider alternative non-opioid pain management or non-benzodiazepine muscle relaxants if appropriate.
Patients may experience profound sedation, dizziness, confusion, and impaired motor coordination, increasing the risk of falls and accidents. The most serious clinical effect is life-threatening respiratory depression, which can lead to hypoxia, coma, and death. Other effects include hypotension and severe constipation.
Mechanism
Both morphine (an opioid analgesic) and orphenadrine (a skeletal muscle relaxant with anticholinergic properties) exert central nervous system (CNS) depressant effects. The co-administration leads to an additive depressant effect on the CNS, intensifying sedation, respiratory depression, and psychomotor impairment. Orphenadrine's anticholinergic effects can also contribute to confusion and delirium, particularly in susceptible patients.
Clinical Management
Concomitant use should generally be avoided due to the high risk of severe adverse effects. If co-administration is unavoidable, patients should be closely monitored for signs of CNS and respiratory depression, especially during initiation or dose adjustments of either drug. Lower doses of both medications should be considered, and patients should be educated on the risks and advised against operating heavy machinery or driving.
The combination significantly increases the risk of severe respiratory depression, profound sedation, coma, and death. Patients may experience decreased level of consciousness, hypoventilation, bradycardia, and hypotension. These effects can be life-threatening if not promptly recognized and managed.
Mechanism
Both morphine (an opioid agonist) and clonazepam (a benzodiazepine) are central nervous system (CNS) depressants. Opioids primarily act on mu-opioid receptors, while benzodiazepines enhance the effect of the inhibitory neurotransmitter GABA at GABA-A receptors. The co-administration of these agents leads to an additive and synergistic depressant effect on the CNS, particularly on respiratory drive and consciousness.
Clinical Management
Avoid co-prescribing opioids and benzodiazepines whenever possible. If co-administration is unavoidable, prescribe the lowest effective doses for the shortest possible duration, and closely monitor patients for signs of respiratory depression and sedation. Educate patients and caregivers about the risks and symptoms, and consider prescribing naloxone for opioid overdose reversal. Consider alternative non-opioid or non-benzodiazepine therapies.
The primary clinical effects include severe respiratory depression, profound sedation, somnolence, coma, and potentially death. Patients may exhibit decreased respiratory rate, shallow breathing, hypoxemia, altered mental status, and unresponsiveness. These effects can occur rapidly and are dose-dependent.
Mechanism
Both morphine (an opioid agonist) and diazepam (a benzodiazepine) are central nervous system (CNS) depressants. Morphine primarily acts on mu-opioid receptors, while diazepam enhances the effect of the inhibitory neurotransmitter GABA at GABA-A receptors. Their combined CNS depressant effects are synergistic, leading to profound and potentially life-threatening respiratory depression and sedation.
Clinical Management
Coadministration should generally be avoided due to the high risk of severe adverse outcomes. If coadministration is absolutely necessary, use the lowest effective doses and shortest possible duration, closely monitor for respiratory depression and sedation, and educate patients and caregivers on the risks. Naloxone and flumazenil should be readily available for emergency reversal.
Patients may experience severe respiratory depression, characterized by decreased respiratory rate and depth, hypoxemia, and hypercapnia. Profound sedation, stupor, coma, and death are significant risks. Other effects include increased risk of accidental overdose, psychomotor impairment, and hypotension.
Mechanism
Morphine, an opioid agonist, primarily acts on mu-opioid receptors in the central nervous system (CNS) to produce analgesia and respiratory depression. Alprazolam, a benzodiazepine, enhances the effect of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) at GABA-A receptors. The synergistic CNS depressant effects of these two drug classes lead to profound respiratory depression, sedation, and hypotension.
Clinical Management
Concomitant use of opioids and benzodiazepines should generally be avoided due to the high risk of severe adverse outcomes, as highlighted by an FDA Black Box Warning. If co-prescription is unavoidable, use the lowest effective doses for the shortest possible duration, closely monitor for respiratory depression and sedation, and educate patients and caregivers on the risks. Consider naloxone co-prescription for at-risk patients.
Patients may experience profound sedation, respiratory depression (decreased respiratory rate and depth), coma, and potentially death. Other symptoms include dizziness, confusion, psychomotor impairment, and hypotension.
Mechanism
Both morphine (an opioid agonist) and oxazepam (a benzodiazepine) are central nervous system (CNS) depressants. Their co-administration leads to additive CNS depression, primarily by enhancing GABAergic neurotransmission (benzodiazepines) and acting on mu-opioid receptors (morphine), resulting in synergistic effects on respiratory drive and sedation.
Clinical Management
Avoid co-prescription if possible. If concomitant use is unavoidable, prescribe the lowest effective doses for the shortest duration possible, monitor closely for respiratory depression and sedation, and educate patients and caregivers on the risks and symptoms. Consider naloxone availability for patients at high risk.
Concomitant use can lead to profound sedation, respiratory depression (decreased respiratory rate and depth), coma, and death. Patients may exhibit somnolence, dizziness, mental confusion, and psychomotor impairment. The combination significantly impairs cognitive and motor function.
Mechanism
Morphine, an opioid agonist, primarily acts on mu-opioid receptors to produce central nervous system (CNS) depression, including respiratory depression and sedation. Triazolam, a benzodiazepine, enhances the effect of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) at the GABA-A receptor, leading to further CNS depression. The synergistic CNS depressant effects of both drugs significantly increase the risk of severe adverse outcomes.
Clinical Management
Avoid concomitant use of morphine and triazolam whenever possible due to the high risk of severe adverse effects, including respiratory depression and death. If concurrent use is unavoidable, prescribe the lowest effective doses for the shortest possible duration, closely monitor patients for signs of respiratory depression and sedation, and educate patients and caregivers on the risks. Consider alternative therapies if clinically appropriate.
The primary clinical effects include profound sedation, respiratory depression (reduced respiratory rate and tidal volume), hypotension, and psychomotor impairment. In severe cases, this can progress to coma, respiratory arrest, and death. Patients may also experience increased dizziness, confusion, and ataxia.
Mechanism
Both morphine (an opioid agonist) and midazolam (a benzodiazepine) are central nervous system (CNS) depressants. Their co-administration leads to an additive and synergistic depressant effect on the CNS, particularly affecting the respiratory drive and level of consciousness. This occurs through distinct but complementary pathways: opioids primarily act on mu-opioid receptors, while benzodiazepines potentiate the effects of GABA at GABA-A receptors, both leading to neuronal inhibition.
Clinical Management
Co-administration should generally be avoided due to the significant risks, as highlighted by the FDA Black Box Warning. If absolutely necessary, use the lowest effective doses of both medications, limit duration, and ensure close monitoring for respiratory depression and sedation. Have resuscitation equipment and opioid antagonists (e.g., naloxone) readily available. Consider alternative therapies if possible.
For complete prescribing information:
View full MORPHINE monograph →Medical Disclaimer
The information on RxGuide is intended for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician, pharmacist, or other qualified health provider with any questions you may have regarding a medical condition or medication. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.